Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market
Cosmos Health (NASDAQ:COSM) has filed a patent application (N2039644) for a multiple sclerosis (MS) treatment, leveraging its AI-powered Cloudscreen drug repurposing platform. The initiative stems from the company's collaboration with Cloudpharm and the National Hellenic Research Foundation, supported by NLO's pharma patent experts.
The patent application is based on data-driven in silico evidence and simulations, along with experimental validation, identifying a unique mechanism of action in a repurposed marketed drug for MS treatment. This development targets the growing MS market, which was valued at $25.94 billion in 2023 and is expected to grow at a 5.9% CAGR from 2024 to 2030.
Multiple sclerosis, affecting 2.9 million people globally as of 2023, is a chronic autoimmune disorder impacting the central nervous system. The global market growth is driven by therapeutic advancements, increased healthcare investments, and ongoing research addressing unmet patient needs.
Cosmos Health (NASDAQ:COSM) ha presentato una domanda di brevetto (N2039644) per un trattamento della sclerosi multipla (SM), sfruttando la sua piattaforma di riposizionamento dei farmaci Cloudscreen potenziata dall'IA. Questa iniziativa deriva dalla collaborazione dell'azienda con Cloudpharm e la Fondazione Nazionale Ellenica di Ricerca, supportata dagli esperti di brevetti farmaceutici di NLO.
La domanda di brevetto si basa su evidenze e simulazioni in silico guidate dai dati, insieme a una convalida sperimentale, identificando un meccanismo d'azione unico in un farmaco già commercializzato riposizionato per il trattamento della SM. Questo sviluppo si rivolge al crescente mercato della SM, valutato 25,94 miliardi di dollari nel 2023 e si prevede crescerà a una CAGR del 5,9% dal 2024 al 2030.
La sclerosi multipla, che colpisce 2,9 milioni di persone a livello globale nel 2023, è un disturbo autoimmune cronico che influisce sul sistema nervoso centrale. La crescita del mercato globale è spinta dai progressi terapeutici, dagli investimenti crescenti nel settore sanitario e dalla ricerca in corso che affronta le esigenze insoddisfatte dei pazienti.
Cosmos Health (NASDAQ:COSM) ha presentado una solicitud de patente (N2039644) para un tratamiento de la esclerosis múltiple (EM), aprovechando su plataforma de reposicionamiento de medicamentos Cloudscreen impulsada por IA. Esta iniciativa surge de la colaboración de la empresa con Cloudpharm y la Fundación Nacional de Investigación Helénica, respaldada por los expertos en patentes farmacéuticas de NLO.
La solicitud de patente se basa en evidencia y simulaciones in silico impulsadas por datos, junto con validación experimental, identificando un mecanismo de acción único en un medicamento comercializado reposicionado para el tratamiento de la EM. Este desarrollo apunta al creciente mercado de la EM, que fue valorado en $25.94 mil millones en 2023 y se espera que crezca a una tasa compuesta anual del 5.9% desde 2024 hasta 2030.
La esclerosis múltiple, que afecta a 2.9 millones de personas en todo el mundo en 2023, es un trastorno autoinmunitario crónico que impacta el sistema nervioso central. El crecimiento del mercado global se impulsa por avances terapéuticos, mayores inversiones en salud y la investigación continua que aborda las necesidades insatisfechas de los pacientes.
코스모스 헬스 (NASDAQ:COSM)는 인공지능 기반 클라우드 스크린 약물 재활용 플랫폼을 활용하여 다발성 경화증(MS) 치료를 위한 특허 신청(N2039644)을 제출했습니다. 이 계획은 클라우드팜과 헬레닉 국립 연구 재단과의 협력에서 비롯되었으며, NLO의 제약 특허 전문가들이 지원하고 있습니다.
특허 신청은 데이터 기반의 실리코 증거와 시뮬레이션, 실험 검증을 바탕으로 하며, MS 치료를 위한 재활용된 상용 약물에서 독특한 작용 메커니즘을 식별합니다. 이 개발은 2023년 259억 4천만 달러로 평가된 증가하는 MS 시장을 겨냥하고 있으며, 2024년부터 2030년까지 연평균 5.9% 성장할 것으로 예상됩니다.
2023년 현재 전 세계적으로 290만 명이 영향을 받고 있는 다발성 경화증은 중추 신경계에 영향을 미치는 만성 자가 면역 질환입니다. 세계 시장의 성장은 치료법 발전, 증가하는 의료 투자 및 환자의 미충족 요구를 해결하는 지속적인 연구에 의해 추진되고 있습니다.
Cosmos Health (NASDAQ:COSM) a déposé une demande de brevet (N2039644) pour un traitement de la sclérose en plaques (SEP), en s'appuyant sur sa plateforme de repositionnement médicamenteux Cloudscreen alimentée par l'IA. Cette initiative découle de la collaboration de l'entreprise avec Cloudpharm et la Fondation Nationale Hellénique de Recherche, soutenue par les experts en brevets pharmaceutiques de NLO.
La demande de brevet repose sur des preuves in silico et des simulations basées sur des données, ainsi que sur une validation expérimentale, identifiant un mécanisme d'action unique dans un médicament commercialisé repositionné pour le traitement de la SEP. Ce développement vise le marché croissant de la SEP, qui était évalué à 25,94 milliards de dollars en 2023 et devrait connaître une croissance annuelle de 5,9 % entre 2024 et 2030.
La sclérose en plaques, qui touche 2,9 millions de personnes dans le monde en 2023, est une maladie auto-immune chronique affectant le système nerveux central. La croissance du marché mondial est alimentée par des avancées thérapeutiques, des investissements accrus dans le secteur de la santé et des recherches continues visant à répondre aux besoins non satisfaits des patients.
Cosmos Health (NASDAQ:COSM) hat einen Patentantrag (N2039644) für eine Behandlung der Multiplen Sklerose (MS) eingereicht, der auf seiner KI-gestützten Cloudscreen-Plattform zur Wiederverwendung von Medikamenten basiert. Diese Initiative resultiert aus der Zusammenarbeit des Unternehmens mit Cloudpharm und der Nationalen Griechischen Forschungsstiftung, unterstützt von den Pharma-Patente-Experten von NLO.
Der Patentantrag basiert auf datengestützten in-silico-Evidenzen und Simulationen sowie experimenteller Validierung, die einen einzigartigen Wirkmechanismus in einem wiederverwendeten marktfähigen Medikament zur Behandlung von MS identifiziert. Diese Entwicklung zielt auf den wachsenden MS-Markt ab, der im Jahr 2023 mit 25,94 Milliarden US-Dollar bewertet wurde und voraussichtlich von 2024 bis 2030 mit einer jährlichen Wachstumsrate von 5,9 % wachsen wird.
Die Multiple Sklerose, die 2023 weltweit 2,9 Millionen Menschen betrifft, ist eine chronische Autoimmunerkrankung, die das zentrale Nervensystem beeinträchtigt. Das Wachstum des globalen Marktes wird durch therapeutische Fortschritte, erhöhte Investitionen im Gesundheitswesen und fortlaufende Forschung zur Deckung der ungedeckten Bedürfnisse von Patienten vorangetrieben.
- Patent application filed for MS treatment using AI-driven drug repurposing technology
- Targeting $25.94 billion global MS treatment market with 5.9% projected CAGR (2024-2030)
- Strategic partnership with Cloudpharm and National Hellenic Research Foundation
- None.
Insights
Cosmos Health's patent filing for Multiple Sclerosis treatment merits careful analysis from multiple angles. The company's approach of using AI-driven drug repurposing is particularly noteworthy, as it could significantly reduce the traditional $1-2 billion cost and 10+ year timeline typically associated with new drug development.
The strategic value lies in three key aspects:
- The choice of drug repurposing leverages existing safety data and could accelerate the regulatory pathway, potentially reducing development time by 3-5 years
- Partnership with Cloudpharm and the National Hellenic Research Foundation provides important research infrastructure without significant capital investment
- Targeting the $25.94 billion MS market with a
5.9% CAGR offers substantial revenue potential, even with modest market penetration
However, investors should consider several critical factors. The company's market cap of
The patent application's focus on a 'unique mechanism of action' for a repurposed drug could be particularly valuable if it addresses current treatment gaps or offers improved efficacy. However, the path from patent filing to marketable treatment remains long and complex, requiring substantial capital investment and clinical validation.
The Multiple Sclerosis treatment market presents a complex landscape with significant opportunities and challenges. The increase in global MS prevalence to 2.9 million patients in 2023 reflects a growing addressable market, driven by improved diagnosis rates and longer patient survival.
Key market dynamics include:
- Premium pricing potential, with current MS therapies often commanding $60,000-80,000 annual treatment costs
- Strong reimbursement coverage in major markets, particularly in the US and EU
- Increasing demand for novel treatment mechanisms, especially for progressive MS forms
- Growing focus on personalized medicine approaches
While the projected
CHICAGO, IL / ACCESS Newswire / February 5, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company")(NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of a patent application for multiple sclerosis (MS), a disabling autoimmune disorder affecting millions worldwide.
The patent application, filed under Application Number N2039644, represents a significant step forward in the Company's intellectual property strategy. This milestone highlights Cosmos Health's strategic partnership with Cloudpharm and the National Hellenic Research Foundation, supported by the pharma patent expert team at NLO.
The patent is supported by data-driven in silico evidence and simulations generated by Cosmos Health's AI-powered Cloudscreen drug repurposing platform, coupled with robust experimental validation. Recent findings by Cosmos Health have demonstrated the potential of a repurposed marketed drug for treating MS, with the inventors identifying a unique mechanism of action.
These advancements underscore the Company's commitment to tackling the challenges of autoimmune diseases and providing innovative solutions to enhance patient care.
Multiple Sclerosis
Multiple sclerosis is a chronic autoimmune disorder that affects the central nervous system, causing a wide range of symptoms and significant disability. According to the Atlas of MS, the number of individuals living with MS globally has risen from 2.3 million in 2013 to 2.9 million in 2023. With its unpredictable progression, MS presents ongoing challenges for patients and healthcare providers alike.
Global Market Overview
According to Grand View Research, the global multiple sclerosis treatment market has been experiencing steady growth, driven by advancements in therapeutic options and a rising prevalence of the disease. The market was valued at approximately
Greg Siokas, CEO of Cosmos Health, stated: "This patent application is another important addition to our intellectual property portfolio and reflects our dedication to advancing innovative treatments for complex diseases. By focusing on multiple sclerosis, we are addressing a critical medical need and are committed to delivering impactful solutions for patients worldwide."
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
FAQ
What is the market size for multiple sclerosis treatment that COSM is targeting?
What is the patent application number for COSM's multiple sclerosis treatment?
How many people globally are affected by multiple sclerosis according to COSM's report?
What technology is COSM using for its multiple sclerosis treatment development?
Who are COSM's partners in developing the multiple sclerosis treatment?
